Morganti S, Jin Q, Vincuilla J, Buehler R, et al. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ Breast Cancer 2024;10:28.
PMID: 38627457